Pharmaceuticals, Biotechnology & Life Sciences

How aTyr Pharma’s legal storm and short‑seller pressure threaten its protein‑drug pipeline—and what investors should watch for next.

VYNE Therapeutics: A biotech on the brink of breakthrough treatments for chronic itching and coughing, yet grappling with steep stock volatility and near‑zero profitability.

Vaxart’s oral flu vaccine could revolutionize flu prevention, yet the biotech’s steep financial struggles and regulatory hurdles keep its future uncertain.

Exelixis Inc. gains institutional backing and rides a projected rise in rhabdomyosarcoma market, with its Cabozantinib partnership poised to boost growth.

UniQure’s share plunge after the FDA flagged AMT‑130 data highlights regulatory risk, legal investigations, and a bearish market—find out why investors are concerned.

Verrica Pharmaceuticals (VRCA) sees fresh institutional backing as insider buying by John Kirby and Caligan Partners LP fuels optimism for its dermatology pipeline and potential Phase 2 acceleration.

Eurofins Scientific SE: Regulatory updates, food‑safety growth, and strong fundamentals signal solid upside for investors in a booming testing market.

Akebia Therapeutics, a Cambridge‑based biotech, focuses on HIF‑based kidney disease drugs, blending research breakthroughs with investor‑friendly insights.

Arcutis Biotherapeutics: $3.79B Nasdaq biopharma focused on groundbreaking immune‑mediated therapies, strong R&D investment, and a resilient market trajectory.

WuXi AppTec shares fell 3% amid a broader market retreat as U.S. security concerns and a €3 m contract with a military‑linked firm raise investor risk‑wary speculation about its CRO growth prospects.